BPC-157 is not FDA-approved, and patients should only use it under medical supervision
Although approximately 1 in 1500 patients exhibit signs of chronic liver injury in long-term prophylactic therapy, acute liver injury due to NFT is quite rare, with approximately 0.3 cases per 100,000 prescriptions (LiverTox 2020)
Relative risk of mortality and morbidity As per the non-diabetic model, but with benefits specific to the diabetic population
Tirzepatide, the active ingredient in Zepbound, was found to have similar effects during the SURMOUNT-1 trial
These challenges can make even the most dedicated efforts to lose weight feel like an uphill battle
You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first